|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||4.88|
|Dividend & Yield||0.74 (2.23%)|
|1y Target Est||N/A|
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.
This week, Bayer stated that it expects the Monsanto (MON) acquisition to be delayed. Bayer asked for an extension to January 22.
German drugs and pesticides group Bayer (BAYGn.DE) said on Tuesday it was now likely to be early next year before it can complete its $66 billion deal to acquire U.S. group Monsanto (MON.N), later than previously expected. The European Commission has been scrutinizing the proposed takeover with a deadline of Jan. 8 but Bayer said in a statement it had asked the regulator for an extension on the investigation to Jan. 22, to which the EU Commission responded by saying it would take a decision shortly. Liam Condon, head of Bayer's Crop Science division, said: "An anticipated closing of the deal in early 2018 is now more likely than end of 2017." He also expressed his confidence that the EU would give the green light.